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            Chemotherapy is the first line of treatment used in cancer. Chemotherapy drugs 
such as cisplatin, carboplatin and oxaliplatin are used in treatment. Cisplatin enters the 
cell through copper transporter CTR1 by passive diffusion and bind to DNA and proteins. 
Cisplatin is found to inhibit several enzymes targeting cysteine, histidine and methionine 
residues, which are expected to be responsible for its anticancer activity. A better 
understanding of how the size and shape and leaving ligands of platinum complexes 
affect cysteine protease, papain enzyme are studied. This could give new ways to 
optimize anticancer activity. The activity of papain enzyme was measured on UV-Visible 
spectroscopy. The inhibition profile of papain with different platinum (II) complexes, and 
with different combinations was studied.   
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I. INTRODUCTION 
 
A. HISTORY 
Cancer is a large, heterogeneous class of diseases caused by uncontrolled growth of 
cells that destroy adjacent tissues, spreading throughout the body. Cancer is caused when 
cells are irresponsive to normal tissue controls due to genetic damage. These cells rapidly 
multiply and spread to form tumors. 
Cancers are of two types- malignant tumors and benign tumors. Malignant tumors are 
differentiated from benign tumors as they show uncontrollable growth, invade locally, 
and metastasize to distant body parts. Benign tumors grow in one place and lack the 
ability to metastasize. Cancer is the second most common cause of death in the US, 
exceeded only by heart disease. In the US, cancer accounts for nearly 1 of every 4 deaths 
(American Chemical Society, Cancer Facts and figures, 2009). About-one half of all men 
and one-third of all women in US will develop cancer during their lifetimes. 
Cancer is caused by both internal factors (such as hormones, inherited mutations, 
immune conditions) and acquired/environmental factors (such as radiation, diet, tobacco, 
infectious organisms).Various therapies can be used to treat cancer. They include surgery, 
biological therapy, hormone therapy, radiation, targeted therapy and chemotherapy. 
Cancer can also be treated by nanoparticles.1 Chemotherapy is done by treating with 
different chemicals, such as platinum complexes. Another type of chemotherapy is the 
introduction of selenium. 
Several studies have shown that selenium has strong anticancer activity on malignant 
tumors and has marginal effects on benign and normal cells.2 Selenium has an antioxidant 
property that is responsible for cancer prevention. Selenium targets transcription factors 
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and enzymes. Selenium increases activity of p53 resulting in DNA repair induction.3 In a 
double placebo study conducted by Clark and coworkers in 1996 on yeast cells, the 
researchers concluded that low doses of selenium concentration led to cancer prevention 
and moderate to high doses of selenium concentration led to cancer treatment.4 
Paul Ehrich in 1909 published the first book on ‘chemotherapy’.5 In the beginning of 
20th century the era of chemotherapy began. Soon after the first World War the potential 
therapeutic application of a chemical warfare agent, nitrogen mustard gas, was 
investigated by Louis Goodman and Alfred Gilman.6 Their findings launched the use of 
chemical molecules to destroy cancer cells called chemotherapy. The first line of 
treatment is chemotherapy, though it has side effects.  
Over the past 30 years, cancer has been treated by platinum-based drugs with metal 
complexes, notably cisplatin, oxaliplatin and carboplatin.7 These are considered as 
potential anticancer agents. Structural activity relationships for platinum coordination 
compounds class has confirmed that compounds having cis-geometry only can block cell 
growth.8 Cisplatin is a platinum based chemotherapy drug15 used in treatment of various 
types of cancers including sarcomas and carcinomas.12, 16 Cisplatin was approved for use 
in testicular and ovarian cancer by the U.S FDA in 1978. Cisplatin, the most active 
complex, was found to have antitumor activity whereas trans geometry compounds has 
not shown such activity.9, 10 
In 1845, M.Peyrone first described the compound cisplatin; it was known as Peyrone 
salt and the structure was deduced in 1906.11 Barnett Rosenberg, a professor of Michigan 
State University in 1965, discovered the antitumor activity of cisplatin while conducting 
an experiment on bacterial cell growth inhibition.12 
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The second generation platinum drugs include carboplatin.13 Carboplatin has fewer 
side effects than cisplatin but is less active than cisplatin and thus carboplatin requires 
higher dose to be administered. Carboplatin is used to treat ovarian cancer. Third 
generation platinum compounds include oxaliplatin, which is more effective in treating 
colorectal cancer.14 It has been approved in China and Europe for its clinical use. 
Cisplatin, carboplatin and oxaliplatin are administered intravenously rather than orally 
due to its solubility problems. Platinum based drugs are used as anti cancer agents with a 
broad range of anti-tumor activities. 
 B. CHEMISTRY OF CISPLATIN: 
  Most cisplatin derivatives inhibit the growth of cancer cells, having at least one 
N-H group that is responsible for hydrogen bond donor properties.12 
The general formula of platinum anticancer complexes is12: 
                                                     Cis- [PtX2(NHR2)2] 
                                 R = organic fragment 
                                 X= leaving group, such as chloride or (chelating bis) carboxylate  
Platinum has slow ligand-exchange kinetics.7 Pt coordination compounds form Pt-
ligand bonds having thermodynamic strengths as those of typical coordination bonds, but 
weaker than C-N, C-O, C-C double and single bonds.7 The ligand-exchange of Pt 
compounds are slow, which leads to high kinetic stability with ligand exchange reactions 
in a minute to days rather than microseconds to seconds.7 
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C. COPPER TRANSPORTER:  
Cisplatin, carboplatin and oxaliplatin are administered by i.v. due to their insoluble 
nature in aqueous systems. Previous studies indicate cisplatin uptake proceeds linearly 
with time for 60 minutes. Cisplatin enters the cell by passive diffusion due to differences 
in chloride concentration inside and outside the cell.12 Recently it was found that 
platinum concentration inside the cell is directly linked to cellular management of copper. 
 
Figure 3.1 Mechanism of cisplatin uptake and efflux.21 
In an experiment conducted with yeast protein, CTR1, a high affinity copper 
transporter, and cisplatin, it was found that deletion or mutation of CTR1 gene resulted in 
decreased levels of platinum levels and increased resistance to cisplatin.20 
Overexpression of human CTR1 caused accumulation of cisplatin in both yeast and 
mouse cells. 
Cisplatin and copper might interfere with each other’s mutual transport and 
trigger delocalization and degradation of CTR1.21 This protein helps in active influx of 
platinum complexes. It has also been found that efflux proteins are also present for 
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excretion of platinum complexes. The exporter proteins that are involved in the efflux of 
platinum complexes are ATP-binding cassette transporter family C2 (ABCC2, also 
known as Mrp2/AB or ATP7B). Mrp2 is a multi drug resistant protein.22 
Cisplatin enters the cell by passive diffusion. The chloride group of cisplatin is 
replaced by a water molecule due to which it gets activated.12 This activated cisplatin 
enters the nucleus and reacts with DNA, though reaction with proteins is also possible. 
 
D. MECHANISM OF CISPLATIN WITH DNA: 
Platinum complexes enter the cell through diffusion and form [Pt (NH)3(OH2)2]2+ and  
 [Pt (NH)3Cl (OH)2]+ as they undergo aquation due to low cellular concentration of 
chloride ions. These aquated forms are more reactive to cellular targets. These cellular 
targets include DNA or amino acids present in the cell.24 Thus the primary biological 
target for a platinum complex is DNA. The platinum atom of cisplatin interacts 
covalently with the guanine N7 position of DNA and forms 1, 3-intrastand and 1, 2-
intrastrand crosslinks. These intrastrand crosslinks lead to cellular processes such as 
replication arrest, transcription inhibition, cell-cycle arrest, DNA repair or cell death. 
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Figure 3.2 Schematic representation of formation and effects of cisplatin adducts.15  
In the case of carboplatin and oxaliplatin, these interactions with DNA occur at 
the positions where cyclobutane-1, 1-dicarboxylate (CBDCA) and the oxalate ligands are 
attached to platinum respectively.25 Pt-DNA adducts along with the proteins that bind to 
them promote cytotoxicity. 
Binding to DNA leads to distortion of the double helical structure of DNA, thus 
impairing its processing. The 1, 2-intra strand cross links bend DNA significantly 
towards the major groove, exposing a wide shallow minor groove surface, to which 
several proteins bind. 
These proteins include high-mobility group (HMG) proteins, repair proteins, 
transcription factors and Histone H1 proteins.24 Binding of these proteins will lead to 
replication inhibition, transcription inhibition, cell cycle arrest and cell death.  
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E. MECHANISM OF CISPLATIN WITH PROTEINS:  
Disturbance in the natural equilibrium of enzymatic activity of cysteine proteases 
results in protein degradation, which leads to pathological conditions such as cancer, 
neurological disorders and rheumatoid arthritis.26 The normal balance of these enzymes 
can be restored through regulation by protein inhibitors, leading to a drug development 
opportunity. 
Cisplatin is a potential electrophile and is known to react with any nucleophiles, 
including nucleophilic groups on nucleic acids and sulfhydryl groups on proteins. Reedjik 
and co-workers suggested that cisplatin reaction with proteins leads to inactivation of a 
few essential enzymes or proteins contributing to the biological activity of cisplatin.27  
Platinum complexes are known to react with many cell components. Chemical 
preference for ‘soft’ metal platinum for ‘soft’ ligands, such as sulfur-donating ligands 
leads to drug binding to S-containing biomolecules and sulfur donating ligands that are 
present in high concentration inside the cell.28 
Protein binding is known to contribute to platinum anticancer drug toxicity37, 
however it was suggested that platinum reaction with biological thiols is a pathway for 
resistance and detoxification.12 It was found that binding of platinum complexes to 
methionine residues could result in C-terminal cleavage at the residue, resulting in 
regioselective chemical cleavage of proteins under nonbiological conditions.36 Hence Pt 
complexes interaction with protein may be is important. 
Platinum complexes interact with many biomolecules. Amino acids present metal 
ions with a variety of potential donor atoms. The sulfur donor residue in amino acids is 
one of the primary targets owing to its relative softness for platinum.29 In the absence of 
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S-donor groups, platinum can also bind to lone pair of nitrogen atoms of the amino acid 
histidine. Hence platinum complexes mainly target S-containing cysteine, N-containing 
histidine and S-containing methionine.  
Cisplatin also interacts and inhibits proteins like thioredoxin reductase that 
contain a selenocysteine residue that is essential for the activity of the enzyme. This 
inhibition of the enzyme is irreversibile.17 Thioredoxin reductase (TRXR) is a 
selenoprotein, mostly studied in cancer, present in mytochondria and cytoplasm.18 TRXR 
plays a major role in neoplastic growth. It was reported that TRXR is induced in tumor 
and pre-neoplastic cells. High levels of TRXR were found in brain tumor and 
hepatocellular carcinoma cells. The propensity of cancer cells to over express TRXR 
selenoprotein makes it an apparent target in research directed at improved diagnostic and 
effectual drug targets.2 The importance of TRXR expression for tumor cell development 
is exemplified by inhibition experiments. Inhibiting TRXR could possibly prevent cancer.  
Structure of human TRXR2: 
  
Figure 3.1 Three dimensional structure of human TRXR.35 
Active site of TRXR is the selenium (Sec) in the C-terminal redox centre -Gly-
Cys-Sec-Gly-COOH residue.2TRXR is known to be inhibited via reaction with redox 
active residues by electrophilic compounds that have been proposed as a target for 
anticancer therapy. These include drugs such as platinum containing compounds, 
nitrosoureas and arsenicals.19  
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In a theoretical study done on reacting platinum derivatives with cysteine and 
methionine residues it was found that platinum formed stronger Pt-S dative bond with 
cysteine residue than that of methionine residue.30 Cysteine formed irreversible platinum 
adducts. Hence it was concluded by T. Zimmermann that platinum targets cysteine and 
cysteine plays a major role in platinum metabolism.30 
E. PAPAIN 
Papain is also known as papaya protease I or cysteine protease enzyme.31 It is 
obtained from Carica papaya and it is rich in four cysteine endopeptidases including 
papain, chymopapain, glycyl endopeptidase and carcain. Papain has broad specificity.31 It 
has endopeptidase, amidase and esterase activities. The three dimensional structure of 
papain was first identified in1980 by Drenth. 
Structure: 
Papain is a single-chained polypeptide with three disulfide bridges. The 
sulfhyrdryl group is necessary for the activity of the enzyme. Papain has 345 amino acid 
residues.31 Its three dimensional structure consists of two distinct structural domains with 
a cleft between them. This cleft contains the active site, which contains a catalytic diad 
that has been linked to the catalytic triad of chymotrypsin. The catalytic diad is made up 
of the amino acids - cysteine-25 (from which it gets its classification) and histidine-159. 
The mechanism by which it breaks peptide bonds involves deprotonation of Cys-25 by 
His-159. 
The active site of the enzyme include cysteine (C) at 25th position and histidine 
(H) at 159th position. These active site residues provide unique functions to the enzyme. 
Remaining sulfides of the enzyme are found on three distinct disulfide bridges. Cysteine 
  
 
is an α-amino acid. The side chain on cysteine is thiol, which is non
chain participates in enzymatic reactions, serving as a nucleophile. The thiol group of 
cysteine 25 in papain possesses nu
from its interaction with th
Papain Structure: 
Figure 3.4 Three dimensional structure of papai
Sequence: 
IPEYVDWRQKGAVTPVKNQGS*
DCDRRSYGCNGGYPWSALQLVAQYGI
DGVRQVQPYNEGALLYSIANQPVSVVLEAAGKDFQLYRGGIFVGP
AVAAVGYGPNYILIKNSWGTG
Fig 3.5 Sequence papain structure indicating its active site residu
The present research studies the effect of size and shape of amine ligand, and 
leaving groups on platinum complexes with cysteine containing proteins.
investigation on papain enzymes will help us to dis
platinum complexes vary. Platinum complexes 
cysteine active site. 
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-polar. This thiol side 
cleophilic reactivity in its un-ionized form. This results 
e histidine 159-asparagine system.32 
 
n 
C*GSCWAFSAVVTIEGIIKIRTGNLNEYSEQELL
HYRNTYPYEGVQRYCRSREKGPYAAKT
WGENGYIRIKRGTGNSYGVCGLYTSSFYPVK
es. 
cern trends in inhibition as the 
interact with papain enzyme by targeting 
 
CGNKV*DH*
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A. MATERIALS USED
Dimethyl sulfoxide (DMSO), N
(Substrate), L-Cysteine, c
tetrachloroplatinate (K2PtCl
Ethylenediamine platinum (II) d
tetrametylethylenediamine platinum (II)
platinum(II) oxalate- Pt(en)(ox), N, N, N’, N’
oxalate- Pt(Me4en)(ox) were synthesized 
Distilled water is used for dialysis and buffer preparation.
 Figure 3.6 Structure of platinum complexes
B. UV-VISIBLE SPECTROMETER
The uv-visible spectrophotometer model we used is uv
manufactured from SHIMADZU in year 2000.
spectrometer are wavelength: 410 nm, measuring time: 120 seconds (2
seconds (15 minutes). 
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II. EXPERIMENTS 
: 
α-Benzoyl-DL-arginine p-nitroanilide hydrochloride 
is-diamine dichloroplatinum (II)-99%, potassium 
4), papain enzyme were purchased from Sigma Aldrich.
initrate- Pt(en)(NO3)2, N, N, N’, N’- 
-dinitrate- Pt(Me4en)(NO3)2, ethylenediamine 
- tetrametylethylenediamine platinum (II)
previously in our lab. 
 
 
 and leaving ligands.             
: 
-1201, and uv-
 Parameters we used on the uv
 minutes) or 
 
-
1601 
-visible 
900 
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C. PREPARATION OF BUFFER SOLUTIONS:  
The buffer solutions we used are storage buffer (sodium acetate buffer) and phosphate 
buffer. 50m M sodium acetate buffer was prepared by mixing 18 ml of 0.2 M acetic acid 
to 32 ml of 0.2 M sodium acetate and diluted to 200 ml with distilled water. The pH was 
5. 
Phosphate buffer was prepared mixing dibasic potassium phosphate to phosphoric 
acid and made up to 1000ml with distilled water. Then the pH was adjusted to 7.6 with 
phosphoric acid. 
D. METHODS: 
For each platinum (II) complex, three runs of each combination were done. 
a. Without cysteine, without dialysis- 
20 mg of substrate (Nα-Benzoyl-DL-arginine p-nitroanilide hydrochloride) was 
weighed out and made to solution with 230 microliters of DMSO. 
For the stock enzyme: 
10 mg of papain enzyme was weighed. To this we added 1.0 ml of storage buffer 
and gently tilted the vial to get everything in solution. The solution set for 25-30 minutes. 
For control papain: 
 Prepared 400 microliters of stock papain and added 400 microliters of storage buffer. 
For inhibited papain: 
Prepared 400 microliters of stock papain and to this added 400 microliters of platinum 
compound that is in storage buffer. 
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b. With cysteine, with dialysis: 
In the commercial papain, cysteine is mostly inactive. Addition of L-cysteine 
activates inactive papain. L-cysteine breaks the disulphide bridge s of the papain enzyme 
and activates it. This activated enzyme readily reacts with platinum derivatives. 
The unreactive cysteine was removed by membrane dialysis. Membrane dialysis is 
done in membrane tubing. The papain cysteine solution is transferred into membrane 
tubing and suspended in distilled water for 20 minutes. The buffer present in the solution 
and unreactive cysteine penetrated through this membrane tube. After dialysis storage 
buffer is added to the papain cysteine solution. 
Stock sample, control papain and inhibited papain are prepared as discussed by above 
method, except that in stock sample 10 mg of papain is weighed, 1 mg of cysteine is 
added to it and made to solution by dissolving it in storage buffer.  
E. ASSAY: 
Assays will allow us to assess both the rate and the extent of inhibition as a function 
of bulk and leaving ligand. 
The assay of prepared control and inhibited papain samples are done on a uv-visible 
spectrometer.  
For control assay: In a clean vial or microfuge tube, 900 microliters of assay buffer, 5 
microliters of Substrate, and 100 microliters of control papain sample were combined. 
The sample was mixed briefly and gently, and most of the sample was transferred to a 
clean cuvvette. The ∆A/min was recorded for a period of one hour at 410 nm wavelength. 
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For inhibition assay: In a clean vial or microfuge tube, 900 microliters of assay buffer, 5 
microliters of Substrate, and 100 microliters of inhibited papain sample. The sample was 
mixed briefly and gently, and most of the sample was transferred to a clean cuvvette. The 
∆A/min was recorded for a period of one hour at 410 nm wavelength. 
The assay of the samples was carried out for every 15 minutes for about one hour, 
and the activity of the control and inhibited sample was measured. The control assay is 
compared with that of the inhibited sample. Each run of platinum complexes were done 
for three times for precision and reproducibility. The activity of the control sample and 
inhibited sample at a particular time was done simultaneously on a two slot spectrometer. 
The ∆A/min was recorded for both the control and the inhibited sample. The assay was 
done for each platinum complex for two times: three runs for without addition of cysteine 
to the enzyme and without dialysis, the other three runs for with addition of cysteine to 
the enzyme and with dialysis. 
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                                                          III. RESULTS  
Platinum complexes with varying coordination sites and leaving ligand bulk have been 
studies for their interaction with enzyme papain.  
A. OBSERVATION WITH UV- VISIBLE SPECTROSCOPY:  
UV spectroscopy was carried out at fixed intervals by reacting platinum complexes 
with papain. The UV- parameters used were mentioned above. For without cysteine, 
without dialysis- ∆A/min value for the control sample was more when compared to the 
∆A/min value for the inhibited sample for all the platinum complexes.  
For with cysteine, with dialysis- ∆A/min value for the control sample was less for 
cisplatin, K2Pt(Cl)4, Pt(en)(NO3)2, Pt(en)(ox) when compared to the ∆A/min value for the 
inhibited sample. 
B. OBSERVATION WITHOUT CYSTEINE, WITHOUT DIALYSIS: 
 Commercial papain is inactive.31 When papain is reacted with platinum complexes, it 
was found that there was no significant inhibition of the enzyme.  
a.Cisplatin- no cysteine, no dialysis: 
 
Figure 3.7 Enzymatic Assay of commercial papain with cisplatin. 
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The assay is done for every 15 minutes for about one hour. The graph is plotted 
for the activity versus time. Enzymatic activity is defined as ∆A/minute. The control line 
indicates the control papain sample and the inhibited line indicates the activity of 
inhibited cisplatin sample over a period of time. The black line present on the control and 
inhibited samples indicates the error bars for both the assays. Error bars represent the 
standard deviation of each control and inhibited papain. 
In the above graph it is seen that the control line is above the inhibited line. The 
error bars of the control and inhibited samples overlap at 15 and 60 minutes. The error 
bars at 30, 45 minutes are not overlapped, indicating that cisplatin has significant 
inhibition at these times. 
a.k2PtCl4- no cysteine, no dialysis: 
 
Figure 3.8 Enzymatic assay of commercial papain with K2PtCl4  
The above figure represents a graph plotted for activity versus time for every 15 
minutes for about one hour. The control line represents the activity of control papain 
sample and the inhibited line indicates the inhibited K2PtCl4 sample.  
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Here the activity of the control is below the inhibited papain at 15, 30 and 60 
minutes interval. At 45 minutes the inhibited line is below the control.  
The error bars of the control and inhibited papain overlapped at every interval of 
time. Indicating that K2PtCl4 has no significant inhibition. 
a.Pt(en)(NO3)2- no cysteine, no dialysis: 
 
Figure 3.9 Enzymatic assay of commercial papain with Pt(en)(NO3)2. 
The above figure represents a graph plotted for activity versus time for every 15 
minutes for about one hour. The control line represents the activity of control papain 
sample and the inhibited line indicates the inhibited sample Pt(en)(NO3)2.  
Here the activity of the control line is above the inhibited papain at 15, 45 and 60 
minutes interval. At 30 minutes the control line is below the inhibited. 
The error bars of the control and inhibited papain overlapped at every interval of 
time, which indicates this platinum complex does not show significant inhibition. 
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a.Pt(Me4en)(NO3)2 -no cysteine, no dialysis: 
 
Figure 3.10 Enzymatic assay of commercial papain with Pt(Me4en)(NO3)2. 
The above figure represents a graph plotted for activity versus time for every 15 
minutes for about one hour. The control line represents the activity of control papain 
sample and the inhibited line indicates the inhibited sample Pt(Me4en)(NO3)2.  
Here the activity of the control line is below the inhibited line at 15, 30, 45 and 60 
minutes interval.  
The error bars of the control and inhibited papain overlapped at 30, 45 and 60 
minutes but at 15 minutes the error bars did not overlap. Thus, this platinum complex 
does not show significant inhibition. 
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a.Pt(en)(ox)-no cysteine, no dialysis:  
 
Figure 3.11 Enzymatic assay of commercial papain with Pt(en)(ox). 
The above figure represents a graph plotted for activity versus time for every 15 
minutes for about one hour. The control line represents the activity of control papain 
sample and the inhibited line indicates the inhibited sample Pt(en)(ox).  
Here the activity of the control line is on top of the inhibited line at 15, 45 and 60 
minutes interval. At 30 minutes the control line is below the inhibited sample. 
The error bars of the control and inhibited papain overlapped at 15, 30, 45 and 60 
minutes. Thus, this platinum complex does not show significant inhibition. 
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C. OBSERVATION WITH CYSTEINE AND WITH DIALYSIS 
a.Cisplatin- with cysteine, with dialysis: 
 
Figure 3.12 Enzymatic assay of activated papain with cisplatin.  
The above figure represents a graph plotted for activity versus time for every 15 
minutes for about one hour. The control line represents the activity of control papain 
sample and the inhibited line indicates the inhibited sample cisplatin.  
Here the activity of the control line is on top of the inhibited line at 15, 30, 45 and 
60 minutes interval. The error bars of the control and inhibited papain are not overlapped 
at 15, 30, 45 and 60 minutes. It indicates that cisplatin shows inhibition of papain 
enzyme. 
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a.K2PtCl4-with cysteine, with dialysis: 
 
Figure 3.13 Enzymatic assay of activated papain with K2PtCl4. 
The above figure represents a graph plotted for activity versus time for every 15 
minutes for about one hour. The control line represents the activity of control papain 
sample and the inhibited line indicates the inhibited sample K2PtCl4.  
Here the activity of the control line is on top of the inhibited line at 15, 30, 45 and 
60 minutes interval. The error bars of the control and inhibited papain are not overlapped 
at 15, 30, 45 and 60 minutes. It indicates that K2PtCl4 shows inhibition on papain 
enzyme. 
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a.Pt(en)(NO3)2- with cysteine, with dialysis: 
 
Figure 3.14 Enzymatic assay of activated papain with Pt(en)(NO3)2. 
The above figure represents a graph plotted for activity versus time for every 15 
minutes for about one hour. The control line represents the activity of control papain 
sample and the inhibited line indicates the inhibited sample Pt(en)(NO3)2.  
Here the activity of the control line is on top of the inhibited line at 15, 30, 45 and 
60 minutes interval. The error bars of the control and inhibited papain are overlapped at 
15, 30, 45 and 60 minutes. It indicates that Pt(en)(NO3)2 could not show significant 
inhibition of the papain enzyme. 
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a.Pt(Me4en)(NO3)2- with cysteine, with dialysis: 
 
Figure 3.15 Enzymatic assay of activated papain with Pt(Me4en)(NO3)2. 
The above figure represents a graph plotted for activity versus time for every 15 
minutes for about one hour. The control line represents the activity of control papain 
sample and the inhibited line indicates the inhibited sample Pt(Me4en)(NO3)2.  
Here the activity of the control line is on top of the inhibited line at 15, 30, 45 and 
60 minutes interval. The error bars of the control and inhibited papain are overlapped at 
15, 30, 45 and 60 minutes. It indicates that could not show Pt(Me4en)(NO3)2 significant 
inhibition of the papain enzyme. 
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a.Pt(en)(ox) with cysteine, with dialysis:  
 
Figure 3.16 Enzymatic assay of activated papain with Pt(en)(ox). 
The above figure represents a graph plotted for activity versus time for every 15 
minutes for about one hour. The control line represents the activity of control papain 
sample and the inhibited line indicates the inhibited sample Pt(en)(ox).  
Here the activity of the control line is on top of the inhibited line at 15, 30, 45 and 60 
minutes interval. The error bars of the control and inhibited papain are overlapped at 15 
minutes but did not overlap at 30, 45 and 60 minutes. It indicates that Pt(en)(ox) could 
show significant inhibition of the papain enzyme. 
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D. OBSERVATIONS WITH LEAVING LIGANDS AND BULKY GROUPS:  
Assays were done with different platinum complexes containing different leaving 
ligands. The leaving ligands include chloro, nitrate, and oxalate groups. 
• The leaving ligands play a major role in the inhibition of the papain enzyme. 
The platinum complexes containing leaving ligands as chloro groups such as potassium 
tetrachloroplatinate and cisplatin showed greater inhibition than other platinum 
complexes. 
• The platinum complexes containing oxalates as leaving ligand showed inhibition. 
It was found the research that bulkiness of the group shows an effect on the inhibition 
profile of the papain enzyme. 
• The platinum complex Pt(Me4en)(NO3)2, having a bulkier group did not show 
significant inhibition on the enzyme. 
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                            IV. DISCUSSION 
Platinum based drugs such as cisplatin, carboplatin and oxaliplatin have been used 
extensively for the treatment of cancer.25 Drug resistance and nephrotoxicity are the 
major limitations of these anticancer drugs.  
This research was an attempt to better understand of how the size and shape of the 
amine ligands affect the reactions of the platinum (II) complexes with papain, 
chymotrypsin and subtilisin enzymes, which could lead to insights about ways to improve 
efficacy of platinum-based drugs in cancer chemotherapy.   
The platinum complexes differ in leaving groups and amount of amine ligand 
bulk. The activity of samples of each complex was measured by UV-Visible 
spectroscopy. Inhibition assays of papain by platinum complexes of 1mg/ml 
concentration were performed for every 15 minutes, for about an hour. The error bar at 
each point represents the mean of three trials, measuring the SD of three trials. The 
activity of the papain enzyme when without cysteine, without dialysis by cisplatin, 
showed significant inhibition as the error bars of control and inhibited were not 
overlapped throughout one hour.  
For other platinum complexes such as Pt(en)(NO3)2, K2PtCl4, Pt(en)(ox) and 
Pt(Me4en)(NO3)2, the errors bars of the control and inhibited samples overlapped 
throughout one hour. Hence it was concluded that these platinum complexes did not show 
significant inhibition on papain when papain was inactivated.  
Inhibition assays were also performed after activating papain by addition of 
cysteine and subsequent dialysis. Cisplatin has shown significant inhibition of the 
enzyme, as the error bars of control and inhibited were far apart. The additional cysteine 
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breaks the disulfide bonds of papain, due to which cisplatin could target the cysteine 
residue leading to its inhibition. 
Platinum complexes Pt(en)(NO3)2, K2PtCl4, Pt(en)(ox) showed relative inhibition 
of papain enzyme upon its activation by cysteine as these complexes are of equal size but 
with different leaving ligands. No noticeable difference in reactivity was observed as a 
function of leaving ligand. 
N, N, N’, N’- tetramethyl ethylene diamine Pt (II)-dinitrate, being a bulkier size, 
could not inhibit papain even upon its activation. Thus, that the platinum complex being 
bulkier did not allow the enzyme to react with the platinum complex. Previously, it was 
found that bulk slows reaction with methionine and guanine residues. 34 These results 
further suggest that reaction with the cysteine in the active site is also showed in separate 
results from our lab. 
The activity of platinum compounds was also seen on subtilisin enzyme and 
chymotrypsin. Subtilisin and chymotrypsin are serine proteases with histidine residues in 
their active sites. Subtilisin and chymotrypsin exhibit different inhibition pattern than 
papain as histidine residue is targeted. Relatively similar methodology was used. The 
activity of the enzymes was measured with varying concentrations of the platinum 
complexes. It was found that the error bars for all of the platinum complexes except 
K2PtCl4 overlapped at each point. Hence the platinum complexes were not able to target 
histidine residues.  
Previous research was done with inhibition assays on different peptides and 
enzymes containing different active sites such as selenocysteine, histidine and cysteine 
residues if platinum derivatives would target and lead to their inhibition. 
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Inhibition of TRXR by cisplatin was studied by Tetsuro and co-workers on HeLa 
cells, to see if the cisplatin targetetted selenium residue of TRXR.32The activity of TRXR 
was measured by insulin-reducing assay, and found that cisplatin targeted selenocysteine 
residue of TRXR leading to its inhibition. From our research it was found that cisplatin 
derivatives targeted cysteine residue of papain enzyme leading to its inhibition. In the 
study done on TRXR, researchers concluded that cisplatin showed time and dose 
dependent inhibition on TRXR.32 Our research on papain, we have seen for time 
dependent inhibition, with mg of cisplatin. Inhibition assays on papain are done at 15, 30, 
45, 60 minutes as that done with TRXR. TRXR showed inhibition at 45 minutes, with 
cisplatin concentration being 10, 20 and 30µM. Papain showed inhibition at 15 minutes 
with cisplatin. Thus, we conclude that cisplatin targets cysteine residue over 
selenocysteine, leading to papain inhibition in less time than that of TRXR. However, we 
note that higher concentrations of platinum complexes are utilized in our study. 
Similar research was done by Mohammad and co-workers to see if cis-
diamminediaquaplatinum(II) (PDC) and observed if cisplatin targets histidine residue of 
acetyl choline esterase enzyme (AChE). 33 AChE activity was measured by 
spectrophotometric method of Ellman et al with varying concentrations of cisplatin for a 
period of 30 minutes. They concluded that at 30 minutes PDC showed significant 
inhibition of AChE, and found that histidine residues were targeted by PDC leading to its 
inhibition. Our assay done on papain showed inhibition at 15 minutes by cisplatin. Thus, 
both cysteine and histidine are targeted by cisplatin. 
Similar research was done to see if platinum derivatives target cysteine residue 
and would lead to inhibition of cysteine protease enzyme Cathepsin-B,27  a thiol 
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dependent enzyme. At the active site of cathepsin-B, the conserved cysteine residue 
catalyzes the hydrolysis of amide bonds in proteins and peptides.27 The assay was done 
by treating samples with DCG-0N active labels.27 Researchers concluded that platinum 
derivatives could not inhibit cathepsin-B. We performed a similar assay except for 
treating with active label and SDS- page gel. In our research, it was found that cisplatin 
derivatives targeted cysteine residue leading to significant inhibition of papain enzyme. 
The main reason for lack of cathepsin-B inhibition by platinum derivatives was 
assumed to be that the active site cathepsin-B was large enough to accommodate Pt (II) 
moiety and the binding kinetics of Pt (II) was too slow for efficient inhibition of 
cathepsin-B.27 Pt (II) might have reacted with different residue other than the active site.It 
was found that a free cysteine amino acid has the ability to replace all or at least three of 
four amine ligand groups that surrounded the platinum atom, suggesting that the platinum 
compound was highly reactive to bind free cysteine residues.27 
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                                                V. CONCLUSION  
The reactions of platinum complexes with enzymes were possible to monitor by 
the use of UV-visible spectroscopy, and enzymatic assays. 
This research was conducted to study the effects of leaving groups and bulk of 
protein active sites on the reaction of platinum complexes with cysteine and histidine 
containing proteins. In order to evaluate effects of increased bulk on protein in a platinum 
complex, the reaction of less bulky Pt(en)(NO3)2 shown in figure 3.14 was compared 
with Pt(Me4en)(NO3)2, figure 3.15 and concluded that more bulky ligands slows down 
the reaction with cysteine residue. To understand how the change in leaving groups affect 
the reactions of platinum complex with cysteine containing enzymes, platinum with 
almost same bulk but with different leaving groups were studied. As K2PtCl4 has same 
amount of bulk as cisplatin, the results from the reactions of these two platinum 
complexes were used to understand the effects of leaving group. 
We saw that chloride, nitrate and oxalate are excellent leaving groups, as the error 
bars for these platinum complexes did not overlap resulting in inhibition of cysteine 
protease enzyme papain. 
The main target for the platinum complexes is the cysteine residues over the 
histidine residues. Papain was significantly inhibited by platinum complexes when it was 
activated by addition of cysteine and subsequent dialysis. 
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